Can I Take Rhodiola With Rezdiffra (Resmetirom)?

What Is Resmetirom (Rezdiffra) and How Does It Work?

Resmetirom is a first-in-class, liver-directed thyroid hormone receptor beta (THR-beta) agonist approved by the FDA on March 14, 2024, specifically for adults with noncirrhotic MASH and moderate-to-advanced hepatic fibrosis (stages F2 and F3). It is the first drug approved for this indication. The approved doses are 80 mg or 100 mg orally once daily with food, tiered by body weight.

The THR-Beta Mechanism

THR-beta receptors are expressed heavily in the liver and regulate lipid synthesis, beta-oxidation of fatty acids, and bile acid metabolism. By selectively activating THR-beta rather than the cardiac THR-alpha subtype, resmetirom reduces intrahepatic triglyceride accumulation without the tachycardia or bone density loss that would accompany a non-selective thyromimetic agent. In the MAESTRO-NASH trial (N=966), the 100 mg dose achieved MASH resolution without worsening fibrosis in 25.9% of patients versus 14.2% on placebo (P<0.001), and fibrosis improvement of at least one stage in 29.9% versus 19.9% on placebo (P<0.001) at 52 weeks [1].

Resmetirom's Metabolic Pathway

Resmetirom is metabolized primarily by CYP3A4, with minor contributions from CYP2C8. The FDA prescribing information for Rezdiffra notes that concomitant use of strong CYP3A4 inhibitors increases resmetirom exposure and that dose adjustments or avoidance may be needed [2]. This pathway is directly relevant when evaluating rhodiola, as discussed below.

What Is Rhodiola and Why Do MASH Patients Take It?

Rhodiola rosea is a perennial flowering plant native to Arctic and mountainous regions of Europe and Asia. Its root extracts are classified as adaptogens, a functional category describing plants proposed to help the body adapt to physical and psychological stress. Patients managing MASH often seek energy support, stress reduction, or mood stabilization, making rhodiola a commonly encountered supplement in this population.

Active Compounds in Rhodiola

The principal bioactive constituents are rosavins (rosavin, rosin, rosarin) and salidroside (also called p-tyrosol-glucoside). Standardized extracts typically contain 3% rosavins and 1% salidroside. Salidroside has shown antioxidant, anti-inflammatory, and mild hepatoprotective effects in animal models, which may make it intuitively appealing to patients with liver disease, even though clinical evidence for its hepatoprotective benefit in humans remains limited [3].

Rhodiola's Serotonergic and MAO-Inhibiting Properties

Several in-vitro studies have identified that rhodiola extract inhibits both MAO-A and MAO-B enzymes. A 2000 study published in Phytomedicine reported that rhodiola extracts reduced MAO-A activity by approximately 40% and MAO-B activity by approximately 32% at pharmacologically relevant concentrations [4]. MAO inhibition increases the availability of serotonin, dopamine, and norepinephrine at synapses. This matters clinically because any drug with serotonergic properties, when combined with a MAO inhibitor, can theoretically raise central serotonin tone.

Does Rhodiola Interact With Resmetirom? The Two Pathways

No published randomized controlled trial, pharmacokinetic study, or case series has examined the combination of resmetirom and rhodiola directly. The concern is mechanistic, not empirically confirmed. Two distinct pathways deserve careful attention.

Pathway 1: Pharmacokinetic Interaction via CYP3A4

Resmetirom depends heavily on CYP3A4 for hepatic clearance. Rhodiola salidroside and its aglycone p-tyrosol have been shown in in-vitro CYP inhibition assays to interact with CYP3A4, though the magnitude of this effect in living humans at standard supplement doses remains uncertain [5].

If rhodiola acts as even a modest CYP3A4 inhibitor in vivo, it could reduce the clearance of resmetirom, raising plasma drug concentrations. Higher-than-intended resmetirom exposure may amplify side effects documented in MAESTRO-NASH, including nausea (reported in 19.4% of 100 mg group), diarrhea (15.9%), and dose-dependent increases in ALT or AST [1]. Conversely, if other rhodiola constituents mildly induce CYP3A4 (some botanical polyphenols do both, depending on concentration), they could reduce resmetirom levels and blunt therapeutic efficacy.

The honest answer here: the direction of this interaction is not predictable without human pharmacokinetic data on this specific pairing.

Pathway 2: Pharmacodynamic Interaction via MAO Inhibition and Serotonergic Activity

Resmetirom acts on thyroid hormone pathways, not serotonin pathways, based on its primary mechanism. However, thyroid hormone signaling does modulate serotonergic neurotransmission indirectly. Thyroid hormones upregulate serotonin receptors and increase serotonin synthesis [6]. A THR-beta agonist may therefore create a milieu of mildly elevated serotonin responsiveness in the CNS.

Rhodiola's MAO-inhibitory activity could add to this by slowing serotonin breakdown. The combination does not meet criteria for a true serotonin syndrome risk in the way that an SSRI combined with a full MAOI would, but borderline serotonergic symptoms such as restlessness, mild tremor, or insomnia could theoretically be potentiated. Patients who already take SSRIs, SNRIs, or other serotonergic agents alongside Rezdiffra face a compounded picture that warrants extra scrutiny.

A Clinical Decision Framework for the Resmetirom-Rhodiola Combination

The following four-tier framework is intended to guide the conversation between patient and prescriber, not to replace it.

Tier 1 (Lowest concern): Patient taking resmetirom 80 mg, no other serotonergic drugs, rhodiola at 200 mg/day or less, normal baseline LFTs. Disclosure to prescriber is sufficient; close symptom monitoring every 4 weeks is reasonable.

Tier 2 (Moderate concern): Patient taking resmetirom 100 mg, rhodiola at 400-600 mg/day, or with mildly elevated baseline ALT. The prescriber should review full supplement list, repeat LFTs at 4 and 8 weeks after adding rhodiola, and counsel on serotonin-related warning symptoms.

Tier 3 (Higher concern): Patient taking any serotonergic medication (SSRI, SNRI, triptans, tramadol) in addition to resmetirom, and seeking to add rhodiola. Discuss benefit-risk explicitly. Consider substituting a non-serotonergic adaptogen such as ashwagandha (with its own separate interaction profile to evaluate) or addressing fatigue through lifestyle measures first.

Tier 4 (Avoid until data exist): Patient with already-elevated LFTs on resmetirom therapy, or any prior episode of serotonin-related adverse effects. Rhodiola should be avoided until a clinician determines that hepatic and serotonergic risk is acceptably low.

Hepatic Considerations: Is Rhodiola Hard on the Liver?

This is an important sub-question for anyone taking Rezdiffra, because the underlying disease, MASH, already reflects impaired hepatic function and ongoing inflammation.

Rhodiola and Hepatotoxicity Data

Published case reports of rhodiola-associated hepatotoxicity are rare. LiverTox, the NIH's clinical database of drug-induced liver injury, categorizes rhodiola as "unlikely cause of clinically apparent liver injury" based on available postmarketing data [7]. Animal studies using very high doses of salidroside have shown hepatoprotective effects through Nrf2 pathway activation, but these doses (50-100 mg/kg in rodents) do not translate linearly to human supplementation levels.

Patients with F2-F3 hepatic fibrosis, the population receiving Rezdiffra, may have reduced capacity to handle any additional hepatic metabolic burden. Even a supplement that is benign in a healthy liver could behave differently in a fibrotic one. The Rezdiffra prescribing label itself states the drug has not been studied in patients with decompensated cirrhosis, reflecting that the fibrotic liver is already under surveillance [2].

What ALT and AST Monitoring Looks Like in Practice

The MAESTRO-NASH safety data showed that ALT increases of more than three times the upper limit of normal occurred in 3.5% of the 100 mg resmetirom group at 52 weeks [1]. Clinicians typically monitor liver enzymes at baseline, at 4 weeks, at 12 weeks, and then every 3-6 months during stable therapy. Adding an herbal supplement with any CYP3A4 interaction potential should prompt a repeat LFT check at 4-8 weeks post-introduction.

Thyroid Function Monitoring With Resmetirom: Does Rhodiola Affect This?

Resmetirom's mechanism involves activating THR-beta. The prescribing label requires TSH and free T4 monitoring because the drug can suppress TSH through negative feedback, and some patients on resmetirom develop subclinical thyroid changes [2]. Rhodiola, through its adaptogenic effects on the hypothalamic-pituitary-adrenal (HPA) axis, may modulate HPA-axis signaling, and there is limited evidence it can affect thyroid-stimulating hormone levels in some individuals, though this is poorly characterized in clinical trials [8].

The theoretical concern: if rhodiola modulates HPA or HPT (hypothalamic-pituitary-thyroid) axis tone while resmetirom is simultaneously acting on THR-beta, interpreting a TSH result becomes less straightforward. This does not prohibit the combination, but it does argue for informing the clinician who is monitoring thyroid function.

What Resmetirom's Prescribing Label Says About Supplements

The FDA prescribing information for Rezdiffra does not specifically address herbal supplements or adaptogens. It does address pharmacokinetic drug interactions, noting that strong CYP3A4 inhibitors (such as itraconazole and clarithromycin) should be avoided or managed with dose reduction [2]. The label also identifies that transporters OATP1B1 and OATP1B3 are involved in resmetirom hepatic uptake, and inhibition of these transporters (as occurs with rifampicin or some statin co-administration) can raise systemic exposure significantly.

Rhodiola has not been formally tested against these transporters in published literature, representing a true data gap.

The American Association for the Study of Liver Diseases (AASLD) guidance on MASH management notes that patients should disclose all herbal and dietary supplements to their care team, stating: "Herbal and botanical products may affect hepatic metabolism and should be systematically reviewed in all patients with chronic liver disease" [9].

How to Talk to Your Doctor About This Combination

Patients are sometimes reluctant to disclose supplement use, fearing judgment or dismissal. A straightforward approach works best. At your next Rezdiffra follow-up, say: "I have been taking rhodiola rosea [dose and brand], and I want to know if it is safe alongside my resmetirom."

Bring the product label so your clinician can see the exact rosavins and salidroside percentages. If your provider is unfamiliar with rhodiola's pharmacology, the Natural Medicines database (naturalmedicines.therapeuticresearch.com) is a subscription resource that many hospital pharmacies access and that provides interaction ratings based on available mechanistic and clinical evidence.

If your prescriber clears the combination, request a follow-up LFT panel and a brief symptom check at 4 weeks. Track any new symptoms: changes in sleep, tremor, racing heart, nausea, or mood shifts. These could signal either hepatic stress or serotonergic overstimulation.

Practical Alternatives If Rhodiola Is Not Recommended

Some patients take rhodiola specifically for fatigue, which is a common symptom in MASH. If your clinician advises against rhodiola during resmetirom therapy, several alternatives have more reassuring safety profiles in liver disease:

• Coenzyme Q10 (100-300 mg/day): No known CYP3A4 interaction at standard doses; some small trials suggest modest fatigue benefit in metabolic disease.
• Magnesium glycinate (300-400 mg/day): Widely used for sleep and stress; no hepatic interaction concern documented with resmetirom.
• Structured aerobic exercise: The AASLD and the European Association for the Study of the Liver (EASL) both recommend 150-300 minutes per week of moderate-intensity physical activity as part of MASH management [9].

None of these are direct replacements for rhodiola's adaptogenic profile, and each has its own considerations. Discuss them as a menu of options rather than automatic substitutes.

Summary of Known and Theoretical Interaction Risk

| Interaction Type | Mechanism | Evidence Level | Clinical Significance | |---|---|---|---| | CYP3A4 competition | Resmetirom clearance via CYP3A4; rhodiola in-vitro CYP3A4 activity | In-vitro only | Uncertain direction; warrants LFT monitoring | | MAO inhibition / serotonergic | Rhodiola inhibits MAO-A/B; thyroid hormones modulate serotonin receptors | Mechanistic / in-vitro | Low-to-moderate concern; higher if SSRIs co-prescribed | | Hepatic burden in fibrotic liver | CYP3A4 and transporter competition; additional hepatic processing demand | Theoretical | Warrants follow-up ALT/AST at 4-8 weeks | | Thyroid axis modulation | Rhodiola HPA/HPT effects; resmetirom THR-beta agonism | Animal data only | Complicates TSH interpretation |